A recent study indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional diet and exercise programs.
Research printed in a prominent health publication shows that while overweight individuals often shed a large proportion of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Users purchasing such medications should be informed of the risk of quick rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Analyzing Treatments
The study, which reviewed dozens of trials involving thousands of patients, contrasted the effects of these new drugs with conventional dieting.
Researchers note that people who lose weight through diet and exercise typically see a slower weight regain—around 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Experts believe the mode of action of the jabs is key to understanding the heightened rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making overeating a significant risk."
A Chronic Disease?
Health authorities recommend the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "highlight the chronic character of excess weight," similar to managing diseases like hypertension.
Patient Accounts
Users who have stopped the medication explain a sudden return of hunger.
"It was like something activating and I was suddenly ravenous," recalled an individual.
This difficulty is compounded if individuals have not adopted lasting lifestyle or habit changes during therapy.
Widespread Interest
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Use is greater among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a magic cure and long-term success likely depends on ongoing behavioural support.
